(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of your Number one Sort of Cap - 2Public mistrust linked to drop in deceased donor organ donations and kidney transplants
- 3Governors Ball 2026: Lorde, A$AP Rocky and Stray Kids set to headline
- 4Two Passover initiatives target isolation and safety for Israel’s elderly
- 5More parents refusing this shot that prevents serious bleeding at birth
- Hitler's madcap mega-railway would have linked Berlin with India
- What to expect from the planets in 2026 — key dates and sky events
- Surf Spot Mechanics: Bells Beach
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- Audits of 6 Specialty Mixed drinks
- Manual for Picking Coastline Travel
- Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- Bahrain cracks down on dissent as war grinds on
